Church & Dwight projected its annual net sales forecast above market estimates after posting upbeat fourth-quarter revenue on Friday, boosted by higher prices and resilient demand for its household and personal-care products.
Health insurer Cigna Group raised its 2024 profit forecast on Friday after lower-than-expected medical costs and strong demand in its pharmacy benefit management unit helped it beat fourth-quarter profit estimates, sending its shares up nearly 5% in premarket trading.
AbbVie Inc beat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand for Botox amid stiff competition.
Exchange operator CBOE Global Markets Inc posted a rise in fourth-quarter profit on Friday, driven by a surge in trading volumes on high hopes of a soft landing in the U.S. economy.
Elon Musk's announcement this week that his startup Neuralink had implanted the first human patient with its experimental brain device generated immediate buzz.
Sugar and ethanol firm Raizen and Chinese automaker BYD are joining forces to create a network of 600 charging stations for electric vehicles (EVs) in eight Brazilian cities, the companies said on Friday.
Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid outperformed Wall Street forecasts.
U.S. regional banking stocks could come under pressure on Friday following a brutal sell-off sparked by New York Community Bancorp's earnings that renewed investor focus on the lenders' exposure to the troubled commercial real estate sector.
U.S. safety regulators said they have upgraded their probe into Tesla vehicles over power steering loss to an engineering analysis - a required step before they could potentially demand a recall.
Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target.
Sponsors are not involved in the creation of newsletters or other Reuters news content.
